Literature DB >> 33675011

A Novel Mouse Model for Cerebral Venous Sinus Thrombosis.

Marie-Charlotte Bourrienne1, Stéphane Loyau2, Sandro Benichi3, Juliette Gay2, Mialitiana Solo-Nomenjanahary2, Clément Journé2,4, Lucas Di Meglio2, Aurélien Freiherr von Seckendorff2, Jean-Philippe Desilles2,5, Benoît Ho-Tin-Noé2, Nadine Ajzenberg2,6, Mikaël Mazighi2,5,7.   

Abstract

Cerebral venous sinus thrombosis (CVST) is an uncommon cause of stroke resulting in parenchymal injuries associated with heterogeneous clinical symptoms and prognosis. Therefore, an experimental animal model is required to further study underlying mechanisms involved in CVST. This study is aimed at developing a novel murine model suitable and relevant for evaluating injury patterns during CVST and studying its clinical aspects. CVST was achieved in C57BL/6J mice by autologous clot injection into the superior sagittal sinus (SSS) combined with bilateral ligation of external jugular veins. Clot was prepared ex vivo using thrombin before injection. On days 1 and 7 after CVST, SSS occlusion and associated-parenchymal lesions were monitored using different modalities: in vivo real-time intravital microscopy, magnetic resonance imaging (MRI), and immuno-histology. In addition, mice were subjected to a neurological sensory-motor evaluation. Thrombin-induced clot provided fibrin- and erythrocyte-rich thrombi that lead to reproducible SSS occlusion at day 1 after CVST induction. On day 7 post-CVST, venous occlusion monitoring (MRI, intravital microscopy) showed that initial injected-thrombus size did not significantly change demonstrating no early spontaneous recanalization. Microscopic histological analysis revealed that SSS occlusion resulted in brain edema, extensive fibrin-rich venular thrombotic occlusion, and ischemic and hemorrhagic lesions. Mice with CVST showed a significant lower neurological score on post-operative days 1 and 7, compared to the sham-operated group. We established a novel clinically CVST-relevant model with a persistent and reproducible SSS occlusion responsible for symptomatic ischemic and hemorrhagic lesions. This method provides a reliable model to study CVST physiopathology and evaluation of therapeutic new regimens.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Brain edema; Cerebral venous thrombosis; Experimental animal model; Mouse; Stroke

Mesh:

Year:  2021        PMID: 33675011     DOI: 10.1007/s12975-021-00898-1

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  39 in total

Review 1.  Cerebral venous thrombosis.

Authors:  Suzanne M Silvis; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho
Journal:  Nat Rev Neurol       Date:  2017-08-18       Impact factor: 42.937

2.  Local cerebral blood flow in a rat cortical vein occlusion model.

Authors:  H Nakase; A Heimann; O Kempski
Journal:  J Cereb Blood Flow Metab       Date:  1996-07       Impact factor: 6.200

3.  Near-infrared fluorescent imaging of cerebral thrombi and blood-brain barrier disruption in a mouse model of cerebral venous sinus thrombosis.

Authors:  Dong-Eog Kim; Dawid Schellingerhout; Farouc A Jaffer; Ralph Weissleder; Ching-Hsuan Tung
Journal:  J Cereb Blood Flow Metab       Date:  2005-02       Impact factor: 6.200

4.  Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome.

Authors:  Erwin Stolz; Anousha Rahimi; Tibo Gerriets; Jörg Kraus; Manfred Kaps
Journal:  Clin Neurol Neurosurg       Date:  2005-02       Impact factor: 1.876

5.  Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis.

Authors:  Mutsumi Nagai; Cigdem Erkuran Yilmaz; Daniel Kirchhofer; Charles T Esmon; Nigel Mackman; D Neil Granger
Journal:  Neurosurgery       Date:  2010-03       Impact factor: 4.654

6.  Establishment of a Rat Model of Superior Sagittal-Sinus Occlusion and Recanalization via a Thread-Embolism Method.

Authors:  Wei Wang; Shuwen Mu; Weiming Xu; Shengxiang Liang; Ruhui Lin; Zuanfang Li; Qinghong Liu; Gaocheng Yi; Liang Xue; Shousen Wang
Journal:  Neuroscience       Date:  2019-08-01       Impact factor: 3.590

7.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

8.  Radiological and histological changes following cerebral venous sinus thrombosis in a rat model.

Authors:  Amit Kumar Srivastava; Jayantee Kalita; Mohamad Haris; Rakesh Kumar Gupta; Usha Kant Misra
Journal:  Neurosci Res       Date:  2009-08-26       Impact factor: 3.304

9.  A new thrombosis model of the superior sagittal sinus involving cortical veins.

Authors:  Guangwen Li; Xianwei Zeng; Tailing Ji; Vance Fredrickson; Tony Wang; Mohammed Hussain; Changhong Ren; Jian Chen; Chaitanya Sikhram; Yuchuan Ding; Xunming Ji
Journal:  World Neurosurg       Date:  2012-11-24       Impact factor: 2.104

10.  Alterations of regional cerebral blood flow and oxygen saturation in a rat sinus-vein thrombosis model.

Authors:  H Nakase; A Heimann; O Kempski
Journal:  Stroke       Date:  1996-04       Impact factor: 7.914

View more
  2 in total

1.  Activating cGAS-STING axis contributes to neuroinflammation in CVST mouse model and induces inflammasome activation and microglia pyroptosis.

Authors:  Rui Ding; Haiyan Li; Yaqi Liu; Weiyang Ou; Xifang Zhang; Huihui Chai; Xiaofei Huang; Weijie Yang; Qiujing Wang
Journal:  J Neuroinflammation       Date:  2022-06-10       Impact factor: 9.587

2.  A novel rat model for cerebral venous sinus thrombosis: verification of similarity to human disease via clinical analysis and experimental validation.

Authors:  Shuwen Mu; Yinghong Lin; Yongjun Xu; Xianqing Wei; Zihuan Zeng; Kunzhe Lin; Linghua Zhu; Qinghong Liu; Xingfeng Qi; Liangfeng Wei; Shengxiang Liang; Shousen Wang
Journal:  J Transl Med       Date:  2022-04-11       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.